United States: FDA Hits "Pause" On Regulation Of LDTs

On January 13, 2017, the U.S. Food and Drug Administration (FDA) issued a Discussion Paper on Laboratory Developed Tests (LDTs) (LDTs) (Discussion Paper). The Discussion Paper follows FDA's late 2016 announcement that, contrary to the Agency's earlier reports, it would not issue a final guidance on its proposed oversight of LDTs to allow "for further public discussion on an appropriate oversight approach, and to give our congressional authorizing committees the opportunity to develop a legislative solution." Discussion Paper at page 1.

The Discussion Paper is the FDA's thoughts after synthesizing more than 300 sets of comments on prior drafts of the Guidance (2014 and 2015) as well as comments and suggestions from public meetings and workshops.

Today's Laboratory Testing

Advances in medical technology have increased the use of diagnostic tests to guide therapeutic decisions for many diseases and conditions, especially in the context of personalized medicine. In 2014, citing the need to ensure that certain diagnostic and clinical tests are accurate, consistent and reliable, FDA announced that the Agency was lifting its enforcement discretion over certain LDTs. (FDA Set to Regulate LDTs – Citing Safety Concerns and Advanced Technologies). The 2014 Guidance proposed a risk-based, phased-in framework for oversight of LDTs that was in accordance with FDA’s current regulation of in vitro diagnostic devices (IVDs). Any clinical or diagnostic test that is designed, manufactured and used in a single laboratory is considered by the Agency as an LDT. Historically, LDTs were manufactured in small volumes by local laboratories. These tests were used and interpreted directly by physicians and pathologists working within a single institution. In addition, traditional LDTs were manufactured using components that were legally marketed for clinical use. More recently, LDTs are manufactured with components and instruments that are not legally marketed for clinical use and rely heavily on high-tech instrumentation and software to generate results and clinical interpretations.

Noting the changes in the complexity and use of LDTs, FDA reported that the policy of general enforcement discretion towards LDTs was no longer appropriate, and that historical oversight by the Centers for Medicare & Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) regulations was deficient. Thus, changes in laboratory technology and its use prompted FDA to re-evaluate its prior hands-off approach to regulation.

A Risk-Based Approach to Oversight

The Discussion Paper notes that while there is a growing consensus that additional oversight of LDTs is necessary, there remains disagreement among stakeholders as to which federal agency would be responsible for any additional oversight. Discussion Paper at page 2. In contrast, most stakeholders appeared to agree on the following features:

  • "A risk-based approach to oversight;
  • Independent premarket review for certain tests and for some modified tests;
  • A focus on analytical and clinical validity as the basis for test approval;
  • Risk classification activities;
  • Adverse event reporting;
  • Exemption of certain categories of tests from premarket review;
  • A robust laboratory quality system;
  • 'Grandfathering' for tests available prior to a specific date; and
  • Public availability of test performance information."

Discussion Paper at page 2.

The Agency notes in its Discussion Paper that based on extensive feedback from stakeholders, "several alternatives to what FDA proposed in 2014 should be considered, including:

  • Exempting LDTs already on the market from all FDA oversight except for adverse event and malfunction reporting ('grandfathering'), and exempting traditional LDTs ... and LDTs for public health surveillance from all oversight;
  • Not adopting proposals requesting laboratories to notify FDA of their LDTs on the market because FDA generally would no longer need to classify LDTs currently on the market as the result of 'grandfathering';
  • Providing additional time before FDA would begin actively overseeing certain regulatory requirements; and
  • Shortening the overall phased-in timeframe."

Discussion Paper at page 3.

FDA's 2017 Proposed Approach

The Agency continues to advocate a "risk-based" approach to LDT oversight. FDA’s prospective oversight proposes focusing on new and significantly modified high and moderate risk LDTs. Previously marketed LDTs would not be expected to comply with most or all FDA regulatory requirements. Discussion Paper at page 4. However, new and significantly modified LDTs in certain categories would not be expected to comply with premarket review, quality systems, and registration and listing requirements unless necessary to protect the public health. These "exempt" categories include: low risk LDTs; LDTs for rare diseases; traditional LDTs. LDTs intended solely for public health surveillance; certain LDTs used in CLIA-certified labs; and LDTs intended solely for forensic use.

Because LDTs currently on the market would be "grandfathered" thereby reducing the overall workload on laboratories and FDA, premarket review of new and significantly modified LDTs could be phased-in over 4 years rather than a period of 9 years that was proposed in the 2014 Guidance Document. The new 4 year phase-in would follow the following timeline:

  1. Year One: Serious adverse event and malfunction reporting for all LDTs except traditional LDTs, LDTs intended for public health surveillance, some stem cell/tissue/organ transplantation LDTs, and LDTs intended solely for forensic use;
  2. Year Two: Premarket review for new/modified LDTs with the same intended use as IVD approved under a PMA;
  3. Year Three: Premarket review for new/modified LDTs with the same intended use as a Class II device subject to 510(k) clearance; and
  4. Year Four: Premarket review for new/modified LDTs that do not fall into the above categories.

Discussion Paper at page 5.

The Discussion Paper also reviews the evidence standards for FDA's premarket review of the categories of tests suggested for additional oversight. In addition, the Agency proposes expanding its third party premarket review program to include eligible LDTs, noting programs such as New York State's Clinical Laboratory Evaluation Program. With respect to postmarket surveillance of LDTs, the Agency recommends that laboratories would initially report serious adverse events for all tests except the exempted categories of tests noted above under "Year One" implementation of the review.

Looking Ahead

FDA's 2017 proposal, as outlined in the Discussion Paper, maintains the Agency's original focus on the public's access to reliable, safe and effective medical technologies without unnecessarily discouraging innovation and increasing the cost of providing these technologies. The Discussion Paper notes that while the report does not represent the formal position of FDA nor is it a final version of the LDT guidance documents published in 2014, it is hoped that its publication will continue to advance further public discourse.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions